Abstract
Multiple sclerosis (MS) is a progressive neurodegenerative disease affecting myelin and axons, which is perpetuated by autoreactive lymphocytes and other inflammatory cell types. Because of the multifactorial nature of this disease, therapies targeting a single process may not be sufficient to halt its progression. VIP and PACAP are two neuropeptides shown to regulate multiple aspects of innate and adaptive immunity, and can also act independently on neural cells to promote their survival and regeneration. Animal studies have proven the efficacy of these peptides for the treatment of several models of neural inflammatory disorders, including those which, like MS, have major Th1/Th17 components. In this review, the immunomodulatory actions of VIP and PACAP will be discussed, with particular emphasis on their potential significance in MS.
Keywords: VIP, PACAP, multiple sclerosis, EAE, neuroimmunomodulation, neuropeptides, immunoprivilege, dexamethasone, lipopolysaccharide, ligand flagellin, orchestrate, microglia, granzyme B, tolerogenic, encephalomyelitis, erythroleukemia, mitogen, myelin, glatiramer acetate
Current Pharmaceutical Design
Title: Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis
Volume: 17 Issue: 10
Author(s): Catalina Abad and James A. Waschek
Affiliation:
Keywords: VIP, PACAP, multiple sclerosis, EAE, neuroimmunomodulation, neuropeptides, immunoprivilege, dexamethasone, lipopolysaccharide, ligand flagellin, orchestrate, microglia, granzyme B, tolerogenic, encephalomyelitis, erythroleukemia, mitogen, myelin, glatiramer acetate
Abstract: Multiple sclerosis (MS) is a progressive neurodegenerative disease affecting myelin and axons, which is perpetuated by autoreactive lymphocytes and other inflammatory cell types. Because of the multifactorial nature of this disease, therapies targeting a single process may not be sufficient to halt its progression. VIP and PACAP are two neuropeptides shown to regulate multiple aspects of innate and adaptive immunity, and can also act independently on neural cells to promote their survival and regeneration. Animal studies have proven the efficacy of these peptides for the treatment of several models of neural inflammatory disorders, including those which, like MS, have major Th1/Th17 components. In this review, the immunomodulatory actions of VIP and PACAP will be discussed, with particular emphasis on their potential significance in MS.
Export Options
About this article
Cite this article as:
Abad Catalina and A. Waschek James, Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis, Current Pharmaceutical Design 2011; 17 (10) . https://dx.doi.org/10.2174/138161211795589364
DOI https://dx.doi.org/10.2174/138161211795589364 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Triterpenoids and their Derivatives with Pharmacological Activity Against Neurodegenerative Disorders
Mini-Reviews in Organic Chemistry Pharmacological manipulation of peripheral vascular resistance in special clinical situations after pediatric cardiac surgery
Current Vascular Pharmacology Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mineralocorticoid Receptor Antagonism and Cardiac Remodeling in Ischemic Heart Failure
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Molecular Replacement in Cancer Therapy: Reversing Cancer Metabolic and Mitochondrial Dysfunction, Fatigue and the Adverse Effects of Cancer Therapy
Current Cancer Therapy Reviews Takotsubo-Like Left Ventricular Dysfunction in an HIV-Infected Patient
Current HIV Research Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice
Current Cardiology Reviews Role of Pharmacotherapy in Cardiac Ion Channelopathies
Current Vascular Pharmacology Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar
Current Vascular Pharmacology Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Successful Radiofrequency Ablation of Atrial Flutter Causing Hemodynamic Instability in a Patient with Recent Myocardial Infarction
Current Cardiology Reviews Endoplasmic Reticulum Stress and Bipolar Disorder - Almost Forgotten Therapeutic Drug Targets in the Unfolded Protein Response Pathway Revisited
CNS & Neurological Disorders - Drug Targets MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Recent Advances in Exercise Testing
Current Cardiology Reviews Critical Overview of Applications of Genetic Testing in Sport Talent Identification
Recent Patents on DNA & Gene Sequences Connexin43 and Myocardial Ischemia-Reperfusion Injury
Cardiovascular & Hematological Disorders-Drug Targets Vitamin D and Vitamin D Receptor Activators in Treatment of Hypertension and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry